PL1620082T3 - Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa - Google Patents

Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa

Info

Publication number: PL1620082T3
Authority: PL; Poland
Prior art keywords: inhibitors; glutaminyl; disease; effectors; medical use
Prior art date: 2003-05-05

Application number

PL04731150T

Other languages

English (en)

Inventor

Hans-Ulrich Demuth

Torsten Hoffmann

André J Niestroj

Stephan Schilling

Ulrich Heiser

Original Assignee

Probiodrug Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-05

Filing date

2004-05-05

Publication date

2010-10-29

2004-05-05 Application filed by Probiodrug Ag filed Critical Probiodrug Ag

2010-10-29 Publication of PL1620082T3 publication Critical patent/PL1620082T3/pl

Links

239000003112 inhibitor Substances 0.000 title abstract 2
208000024827 Alzheimer disease Diseases 0.000 title 1
101710095468 Cyclase Proteins 0.000 title 1
201000010374 Down Syndrome Diseases 0.000 title 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
229930195712 glutamate Natural products 0.000 title 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 title 1
239000012636 effector Substances 0.000 abstract 4
102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 abstract 2
108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 abstract 2
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Psychiatry (AREA)
Oncology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Psychology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Pregnancy & Childbirth (AREA)

PL04731150T 2003-05-05 2004-05-05 Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa PL1620082T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US46801403P	2003-05-05	2003-05-05
US46804303P	2003-05-05	2003-05-05
US51203803P	2003-10-15	2003-10-15
EP04731150A EP1620082B9 (en)	2003-05-05	2004-05-05	Medical use of inhibitors of glutaminyl and glutamate cyclases for treating alzheimer's disease and down syndrome
PCT/EP2004/004778 WO2004098625A2 (en)	2003-05-05	2004-05-05	Medical use of inhibitors of glutaminyl and glutamate cyclases

Publications (1)

Publication Number	Publication Date
PL1620082T3 true PL1620082T3 (pl)	2010-10-29

Family

ID=42827350

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04731150T PL1620082T3 (pl)	2003-05-05	2004-05-05	Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa

Country Status (15)

Country	Link
EP (1)	EP1620082B9 (pl)
JP (1)	JP5690463B2 (pl)
CN (1)	CN1784220B (pl)
AT (1)	ATE464889T1 (pl)
AU (2)	AU2004237408C9 (pl)
BR (1)	BRPI0410078A (pl)
CA (1)	CA2524009C (pl)
DK (1)	DK1620082T3 (pl)
EA (1)	EA009291B1 (pl)
HK (1)	HK1089964A1 (pl)
IL (2)	IL171339A (pl)
MX (1)	MXPA05011861A (pl)
NZ (1)	NZ543146A (pl)
PL (1)	PL1620082T3 (pl)
WO (1)	WO2004098625A2 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7381537B2 (en) *	2003-05-05	2008-06-03	Probiodrug Ag	Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
KR20120007079A (ko)	2003-10-15	2012-01-19	프로비오드룩 아게	글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도
AU2004290499C1 (en) *	2003-11-03	2011-02-24	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
BRPI0507485A (pt) *	2004-02-05	2007-07-10	Probiodrug Ag	inibidores novos de glutaminil ciclase
EA013790B1 (ru) *	2004-02-05	2010-06-30	Пробиодруг Аг	Новые ингибиторы глутаминилциклазы
EP1942898B2 (en)	2005-09-14	2014-05-14	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors for treating diabetes
CN102675221A (zh)	2005-09-16	2012-09-19	武田药品工业株式会社	用于制备嘧啶二酮衍生物的方法中的中间体
US7572614B2 (en)	2006-02-24	2009-08-11	Academia Sinica	Crystal structure of soluble glutaminyl cyclase
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US9108948B2 (en)	2006-06-23	2015-08-18	Abbvie Inc.	Cyclopropyl amine derivatives
RU2449989C2 (ru)	2006-06-23	2012-05-10	Эбботт Лэборетриз	Производные циклопропиламина в качестве модуляторов h3-гистаминового рецептора
EP2082041B1 (en)	2006-09-21	2018-03-14	Probiodrug AG	Novel genes related to glutaminyl cyclase
US8889709B2 (en)	2006-09-21	2014-11-18	Probiodrug Ag	Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions
US9277737B2 (en)	2006-09-21	2016-03-08	Probiodrug Ag	Mouse models carrying a knock-out mutation of the QPCTL-gene
EP2089383B1 (en)	2006-11-09	2015-09-16	Probiodrug AG	3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20120070444A1 (en)	2007-01-19	2012-03-22	Probiodrug Ag	IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS
WO2008087197A1 (en) *	2007-01-19	2008-07-24	Probiodrug Ag	In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders
ZA200905537B (en)	2007-03-01	2010-10-27	Probiodrug Ag	New use of glutaminyl cyclase inhibitors
EP2118101B1 (en)	2007-03-09	2012-09-26	Probiodrug AG	Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
ES2533484T3 (es)	2007-04-18	2015-04-10	Probiodrug Ag	Derivados de tiourea como inhibidores de la glutaminil ciclasa
NZ583799A (en)	2007-09-12	2011-12-22	Probiodrug Ag	Transgenic mice comprising a DNA transgene encoding ABeta peptide
US9462793B2 (en)	2008-01-14	2016-10-11	Probiodrug Ag	Mouse carrying a knock-out mutation of the Qpct-gene
MX2011001093A (es) *	2008-07-31	2011-03-15	Probiodrug Ag	Glutaminil ciclasa como un indicador para el diagnostico / pronostico de enfermedades neurodegenerativas.
US8288591B2 (en)	2008-11-20	2012-10-16	Designer Molecules, Inc.	Curing agents for epoxy resins
US8563735B2 (en) *	2008-12-05	2013-10-22	Abbvie Inc.	Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US9186353B2 (en)	2009-04-27	2015-11-17	Abbvie Inc.	Treatment of osteoarthritis pain
DK2475428T3 (en)	2009-09-11	2015-09-28	Probiodrug Ag	Heterocyclic derivatives as glutaminylcyklaseinhibitorer
JP2013505438A (ja) *	2009-09-18	2013-02-14	プロビオドルグエージー	アミロイドβペプチドの検出のための新規アッセイ
WO2011076854A1 (en) *	2009-12-22	2011-06-30	Probiodrug Ag	CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN
JP2013519891A (ja) *	2010-02-18	2013-05-30	プロビオドルグエージー	ピログルタミン酸修飾ｍｃｐ−１を決定することにより炎症性疾患を診断する方法及びグルタミニルシクラーゼの阻害剤のスクリーニング方法
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
CN102791704B (zh)	2010-03-10	2015-11-25	前体生物药物股份公司	谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
US20130012620A1 (en) *	2010-03-17	2013-01-10	Designer Molecules, Inc.	Curing agents for epoxy resins
JP5945532B2 (ja)	2010-04-21	2016-07-05	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
ES2540467T3 (es)	2010-08-19	2015-07-09	Probiodrug Ag	Estructura cristalina de glutaminil ciclasa
WO2012037258A1 (en)	2010-09-16	2012-03-22	Abbott Laboratories	Processes for preparing 1,2-substituted cyclopropyl derivatives
US9822169B2 (en) *	2011-02-17	2017-11-21	Pacific Northwest Diabetes Research Institute	Compositions and methods of use for determination of HE4a
ES2570167T3 (es)	2011-03-16	2016-05-17	Probiodrug Ag	Derivados de benzimidazol como inhibidores de glutaminil ciclasa
EP2742062A2 (en)	2011-08-12	2014-06-18	Probiodrug AG	In vivo screening models for treatment of qc-related disorders
US9138393B2 (en) *	2013-02-08	2015-09-22	The Procter & Gamble Company	Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
EA029451B1 (ru) *	2013-03-15	2018-03-30	Пробиодруг Аг	Новые ингибиторы
JP6902416B2 (ja) *	2016-07-05	2021-07-14	ライオン株式会社	睡眠評価用マーカー及びその用途
DK3658141T3 (da)	2017-07-24	2023-02-06	Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis	Behandling af patologiske tilstande ved direkte og indirekte målretning af Sirpalpha-CD47-interaktion
EP3461819B1 (en)	2017-09-29	2020-05-27	Probiodrug AG	Inhibitors of glutaminyl cyclase
IT202100012173A1 (it) *	2021-05-12	2022-11-12	Univ Degli Studi Roma La Sapienza	Composizioni per l’uso nel trattamento di disabilità intellettiva e di malattie neurodegenerative in un soggetto con Sindrome di Down
TW202317549A (zh)	2021-06-24	2023-05-01	香港商英科智能有限公司	用於治療疾病之β-內醯胺衍生物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9306190A (pt) *	1992-04-01	1998-06-23	Univ Toledo	Composto composiçao farmacéutica e processo para tratar um indivíduo sofrendo de um distúrbio cognitivo ou uma deficiéncia na atençao ou estímulo
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
AU1891295A (en) *	1994-02-22	1995-09-04	Knoll Aktiengesellschaft	Use of 1-(arylalkylaminoalkyl) imidazoles for treating neurological damage
US5552426A (en) *	1994-04-29	1996-09-03	Eli Lilly And Company	Methods for treating a physiological disorder associated with β-amyloid peptide
WO1996038142A1 (en) *	1995-05-30	1996-12-05	Gliatech, Inc.	1h-4(5)-substituted imidazole derivatives
DE122010000020I1 (de)	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6011155A (en)	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
EP2574336A1 (en)	1998-02-02	2013-04-03	Trustees Of Tufts College	Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
US5994379A (en) *	1998-02-13	1999-11-30	Merck Frosst Canada, Inc.	Bisaryl COX-2 inhibiting compounds, compositions and methods of use
WO1999046272A1 (en)	1998-03-09	1999-09-16	Fondatech Benelux N.V.	Serine peptidase modulators
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de)	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
AU5027299A (en)	1998-07-31	2000-02-28	Novo Nordisk A/S	Use of glp-1 and analogues for preventing type ii diabetes
US6172081B1 (en)	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6110949A (en)	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en)	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1228061A4 (en) *	1999-11-12	2004-12-15	Guilford Pharm Inc	DIPEPTIDYL PEPTIDASE IV INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF
GB9928330D0 (en)	1999-11-30	2000-01-26	Ferring Bv	Novel antidiabetic agents
US6380398B2 (en)	2000-01-04	2002-04-30	Novo Nordisk A/S	Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2001055105A1 (en)	2000-01-24	2001-08-02	Novo Nordisk A/S	N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0010183D0 (en)	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en)	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
EP1301187B1 (en)	2000-07-04	2005-07-06	Novo Nordisk A/S	Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
AU2001269123A1 (en)	2000-07-10	2002-01-21	Bayer Aktiengesellschaft	Regulation of human dipeptidyl-peptidase iv-like enzyme
ATE450504T1 (de)	2000-08-10	2009-12-15	Mitsubishi Tanabe Pharma Corp	Prolinderivative und deren verwendung als medikamente
EP1313470A4 (en) *	2000-08-17	2005-02-16	Gliatech Inc	NEW ALICYCLIC IMIDAZOLE AS H 3 ACTIVE SUBSTANCES
IL155116A0 (en)	2000-10-27	2003-10-31	Probiodrug Ag	Pharmaceutical compositions containing as inhibitor of dipeptidyl peptidase iv and of similar enzymes
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
JPWO2002051836A1 (ja)	2000-12-27	2004-04-22	協和醗酵工業株式会社	ジペプチジルペプチダーゼ−ｉｖ阻害剤
MXPA03007349A (es)	2001-02-24	2003-12-04	Boehringer Ingelheim Pharma	Derivados de xantina, su preparacion y su empleo como medicamentos.
US7026316B2 (en)	2001-03-27	2006-04-11	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US6573287B2 (en)	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
US20030013177A1 (en) *	2001-05-23	2003-01-16	Ebens Allen J.	Polynucleotides encoding insect glutaminyl cyclase and uses thereof
ES2257555T3 (es)	2001-06-20	2006-08-01	MERCK & CO., INC.	Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes.
WO2003000180A2 (en)	2001-06-20	2003-01-03	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en)	2001-06-25	2001-08-15	Ferring Bv	Novel antidiabetic agents
DE10154689A1 (de) *	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
CN1471538A (zh)	2001-06-27	2004-01-28	前体生物药物股份有限公司	用于竞争性调节二肽基肽酶iv催化的肽结构
ES2339813T3 (es)	2001-06-27	2010-05-25	Glaxosmithkline Llc	Fluoropirrolidinas como inhibidores de dipeptidil peptidasas.
DE10150203A1 (de)	2001-10-12	2003-04-17	Probiodrug Ag	Peptidylketone als Inhibitoren der DPIV
EP1399420B1 (en)	2001-06-27	2007-12-05	SmithKline Beecham Corporation	Pyrrolidines as dipeptidyl peptidase inhibitors
ES2291477T3 (es)	2001-06-27	2008-03-01	Smithkline Beecham Corporation	Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
JP2004521149A (ja)	2001-06-27	2004-07-15	プロバイオドラッグアーゲー	新規なジペプチジルぺプチダ−ゼｉｖ阻害剤およびそれらの抗癌剤としての使用
WO2003004496A1 (en)	2001-07-03	2003-01-16	Novo Nordisk A/S	Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
WO2003024942A1 (fr)	2001-09-14	2003-03-27	Mitsubishi Pharma Corporation	Derive thiazolidine et son utilisation medicamenteuse
JP2005509603A (ja)	2001-09-19	2005-04-14	ノボ　ノルディスク　アクティーゼルスカブ	Ｄｐｐ−ｉｖ酵素の阻害剤であるヘテロ環化合物
WO2004089366A1 (en) *	2003-04-10	2004-10-21	Pfizer Japan, Inc.	Bicyclic compounds as nr2b receptor antagonists
GB0704100D0 (en)	2006-03-17	2007-04-11	Vodafone Plc	Improvements in an ehspa architecture
EP2342824B1 (de)	2008-11-05	2014-08-20	OSRAM GmbH	Vor kurzschluss geschützte halbbrückenschaltung mit halbleiterschaltern
US8049427B2 (en)	2008-11-25	2011-11-01	Lutron Electronics Co., Inc.	Load control device having a visual indication of energy savings and usage information

2004
- 2004-05-05 AT AT04731150T patent/ATE464889T1/de active
- 2004-05-05 PL PL04731150T patent/PL1620082T3/pl unknown
- 2004-05-05 DK DK04731150.1T patent/DK1620082T3/da active
- 2004-05-05 EP EP04731150A patent/EP1620082B9/en not_active Expired - Lifetime
- 2004-05-05 JP JP2006505377A patent/JP5690463B2/ja not_active Expired - Fee Related
- 2004-05-05 MX MXPA05011861A patent/MXPA05011861A/es active IP Right Grant
- 2004-05-05 BR BRPI0410078-6A patent/BRPI0410078A/pt not_active Application Discontinuation
- 2004-05-05 CA CA2524009A patent/CA2524009C/en not_active Expired - Lifetime
- 2004-05-05 WO PCT/EP2004/004778 patent/WO2004098625A2/en active Application Filing
- 2004-05-05 NZ NZ543146A patent/NZ543146A/en not_active IP Right Cessation
- 2004-05-05 EA EA200501700A patent/EA009291B1/ru not_active IP Right Cessation
- 2004-05-05 AU AU2004237408A patent/AU2004237408C9/en not_active Ceased
- 2004-05-05 CN CN2004800123862A patent/CN1784220B/zh not_active Expired - Fee Related
2005
- 2005-10-10 IL IL171339A patent/IL171339A/en active IP Right Grant
2006
- 2006-09-27 HK HK06110737.1A patent/HK1089964A1/xx not_active IP Right Cessation
2009
- 2009-10-23 AU AU2009227925A patent/AU2009227925B2/en not_active Ceased
2010
- 2010-05-27 IL IL206009A patent/IL206009A/en active IP Right Grant

Also Published As

Publication number	Publication date
WO2004098625A2 (en)	2004-11-18
JP2006525278A (ja)	2006-11-09
IL171339A (en)	2011-11-30
IL206009A0 (en)	2010-11-30
EA009291B1 (ru)	2007-12-28
EP1620082B9 (en)	2010-08-25
AU2004237408B2 (en)	2009-10-01
CN1784220B (zh)	2011-08-03
AU2004237408C1 (en)	2010-04-01
AU2004237408A1 (en)	2004-11-18
AU2004237408C9 (en)	2010-04-15
AU2009227925B2 (en)	2011-12-15
CA2524009A1 (en)	2004-11-18
AU2009227925A1 (en)	2009-11-12
DK1620082T3 (da)	2010-08-16
HK1089964A1 (en)	2006-12-15
CA2524009C (en)	2014-04-29
CN1784220A (zh)	2006-06-07
WO2004098625A3 (en)	2005-06-23
ATE464889T1 (de)	2010-05-15
NZ543146A (en)	2008-09-26
JP5690463B2 (ja)	2015-03-25
EA200501700A1 (ru)	2006-06-30
IL206009A (en)	2017-09-28
EP1620082A2 (en)	2006-02-01
EP1620082B1 (en)	2010-04-21
BRPI0410078A (pt)	2006-05-16
MXPA05011861A (es)	2006-02-17

Publication	Publication Date	Title
PL1620082T3 (pl)	2010-10-29	Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa
CY1110171T1 (el)	2015-01-14	Ιατρικη χρηση αναστολεων γλουταμινικων και γλουταμικων κυκλασων για θεραπεια της ασθενειας του alzheimer και του συνδρομου down
EP1562897A4 (en)	2007-06-27	PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
EP1485381B8 (en)	2010-05-12	Azolylaminoazine as inhibitors of protein kinases
MY142589A (en)	2010-12-15	Benzimidazole derivatives : preparation and pharmaceutical applications
WO2005039548A3 (en)	2005-06-30	Use of effectors of glutaminyl and glutamate cyclases
AU2003220299A1 (en)	2003-09-29	Azinylaminoazoles as inhibitors of protein kinases
AU2003220300A1 (en)	2003-09-29	Compositions useful as inhibitors of protein kinases
IL181987A0 (en)	2007-07-04	Diaminotriazole derivatives and pharmaceutical compositions containing the same
TW200626601A (en)	2006-08-01	Novel compounds
HK1083624A1 (en)	2006-07-07	Hydroxyethylamine derivatives for the treatment ofalzheimer's disease
NO20045677L (no)	2005-02-28	Inhibitorer av JAK- og CDK2-proteinkinaser
MY140840A (en)	2010-01-29	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
CY1107383T1 (el)	2012-12-19	Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
CY1109245T1 (el)	2014-07-02	Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα
IL179206A0 (en)	2007-03-08	Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MY141528A (en)	2010-05-14	Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA05012675A (es)	2006-02-22	Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.
MXPA04004372A (es)	2004-08-11	Derivados heterociclicos de glicinamida y su uso medico.
SG162614A1 (en)	2010-07-29	Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
SE0302756D0 (sv)	2003-10-17	Novel Compounds
MXPA03010205A (es)	2004-03-10	Derivados de acido oxalico.
MXPA06007007A (es)	2007-06-08	Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
IL175358A0 (en)	2006-09-05	1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
CY1110156T1 (el)	2015-01-14	Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης